Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 August 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Bliss GVS Pharma Ltd has demonstrated a significant shift in technical momentum, moving from a mildly bullish to a bullish stance, supported by robust signals across multiple indicators including MACD, Bollinger Bands, and moving averages. This technical evolution coincides with a strong price performance that outpaces the broader Sensex, signalling renewed investor confidence in this small-cap pharmaceutical player.

At Rs 489.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bliss GVS Pharma Ltd locked at its upper circuit of 4.41% on 4 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Bliss GVS Pharma Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early August 2026. Despite a slight dip in daily price, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, and moving averages suggesting cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector.

Bliss GVS Pharma Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Supported by strong weekly and monthly MACD signals and daily moving averages, the pharmaceutical small-cap is demonstrating renewed investor interest despite mixed short-term returns compared to the broader Sensex.

Bliss GVS Pharma Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of late July 2026. Despite a slight dip in daily price, key indicators such as MACD and KST maintain bullish signals on weekly and monthly charts, while moving averages and Bollinger Bands suggest cautious optimism. This article analyses the evolving technical landscape of this small-cap pharmaceutical stock, contextualising its performance against broader market trends and providing a comprehensive view for investors.

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 July 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

At Rs 470.5, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bliss GVS Pharma Ltd locked at its upper circuit of 5.0% on 23 Jul 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 480, sellers were still queuing — but there were no buyers willing to take the other side. Bliss GVS Pharma Ltd locked at its lower circuit of 4.94% on 17 Jul 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.

Bliss GVS Pharma Ltd is currently rated 'Hold' by MarketsMOJO, a rating that was last updated on 12 Nov 2025. While this rating change occurred over seven months ago, the analysis and financial metrics presented here reflect the stock's current position as of 17 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 06 July 2026, providing investors with the latest insights into its performance and outlook.

At Rs 508, sellers were still queuing but buyers were absent, causing Bliss GVS Pharma Ltd to lock at its lower circuit with a 3.62% loss on 3 Jul 2026. The 5% price band limited the daily fall, yet unfilled supply remains a pressing concern.

Surging from a 52-week low of Rs 118.35 to a fresh peak of Rs 552.9 on 30 Jun 2026, Bliss GVS Pharma Ltd has delivered an extraordinary 243.06% return over the past year, vastly outperforming the Sensex’s decline of 8.44%. This milestone reflects a powerful confluence of technical momentum and sustained price strength that has propelled the stock into uncharted territory.

Bliss GVS Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 30 June 2026, with its stock price touching an all-time high of Rs.548.95. This achievement marks a remarkable phase in the company’s market performance, reflecting sustained gains and strong technical momentum.

At Rs 541.1, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bliss GVS Pharma Ltd locked at its upper circuit of 10% on 29 Jun 2026, with buyers queuing and no sellers willing to part with shares.

With a remarkable surge to Rs 511.85 on 29 Jun 2026, Bliss GVS Pharma Ltd has reached a fresh 52-week and all-time high, marking a spectacular rally from its low of Rs 118.35 just a year ago. This price milestone is underpinned by a strong alignment of technical indicators and sustained momentum that has propelled the stock well ahead of its sector and the broader market.

Extending its remarkable rally, Bliss GVS Pharma Ltd touched a fresh all-time high of Rs 503 on 29 Jun 2026, outpacing the broader Sensex which declined marginally by 0.16% on the day. This milestone caps a stunning run where the stock has surged over 223% in the past year, vastly outperforming the benchmark index’s 8.42% decline.